skip to main content
Idioma:
Mostrar Somente
Refinado por: Base de dados/Biblioteca: Academic Search Premier (EB_SDU_P3) remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Focusing on cancer patients' intentions to use psychooncological support: A longitudinal, mixed‐methods study
Focusing on cancer patients' intentions to use psychooncological support: A longitudinal, mixed‐methods study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Focusing on cancer patients' intentions to use psychooncological support: A longitudinal, mixed‐methods study

Tondorf, T. ; Grossert, A. ; Rothschild, S.I. ; Koller, M.T. ; Rochlitz, C. ; Kiss, A. ; Schaefert, R. ; Meinlschmidt, G. ; Hunziker, S. ; Zwahlen, D.

Psycho-oncology (Chichester, England), 2018-06, Vol.27 (6), p.1656-1663 [Periódico revisado por pares]

England: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por
2
Amplification of SKI Is a Prognostic Marker in Early Colorectal Cancer
Amplification of SKI Is a Prognostic Marker in Early Colorectal Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Amplification of SKI Is a Prognostic Marker in Early Colorectal Cancer

Buess, Martin ; Terracciano, Luigi ; Reuter, Jürgen ; Ballabeni, Pierluigi ; Boulay, Jean-Louis ; Laffer, Urban ; Metzger, Urs ; Herrmann, Richard ; Rochlitz, Christoph F.

Neoplasia (New York, N.Y.), 2004-05, Vol.6 (3), p.207-212 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
3
SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer
SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer

BOULAY, J-L ; MILD, G ; LOWY, A ; REUTER, J ; LAGRANGE, M ; TERRACCIANO, L ; LAFFER, U ; HERRMANN, R ; ROCHLITZ, C

British journal of cancer, 2002-09, Vol.87 (6), p.630-634 [Periódico revisado por pares]

Basingstoke: Nature Publishing Group

Texto completo disponível

Citações Citado por
4
Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer

RIBI, K ; ALDRIDGE, J ; PRICE, K. N ; GELBER, R. D ; BERNHARD, J ; PHILLIPS, K.-A ; THOMPSON, A ; HARVEY, V ; THÜRLIMANN, B ; CARDOSO, F ; PAGANI, O ; COATES, A. S ; GOLDHIRSCH, A

British journal of cancer, 2012-05, Vol.106 (10), p.1618-1625 [Periódico revisado por pares]

Basingstoke: Nature Publishing Group

Texto completo disponível

Citações Citado por
5
STRAP Is a Strong Predictive Marker of Adjuvant Chemotherapy Benefit in Colorectal Cancer
STRAP Is a Strong Predictive Marker of Adjuvant Chemotherapy Benefit in Colorectal Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

STRAP Is a Strong Predictive Marker of Adjuvant Chemotherapy Benefit in Colorectal Cancer

Buess, Martin ; Terracciano, Luigi ; Reuter, Jurgen ; Ballabeni, Pierluigi ; Boulay, Jean-Louis ; Laffer, Urban ; Metzger, Urs ; Herrmann, Richard ; Rochlitz, Christoph

Neoplasia (New York, N.Y.), 2004-11, Vol.6 (6), p.813-820 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
6
Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML) : results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK)
Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML) : results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML) : results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK)

ROCHLITZ, C ; LOHRI, A ; BACCHI, M ; SCHMIDT, M ; NAGEL, S ; FOPP, M ; FEY, M. F ; HERRMANN, R ; NEUBAUER, A

Leukemia, 1999-09, Vol.13 (9), p.1352-1358 [Periódico revisado por pares]

London: Nature Publishing

Texto completo disponível

Citações Citado por
7
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial

MORANT, R ; BERNHARD, J ; GSCHWEND, A ; HANSELMANN, S ; HERING, F ; SCHMID, H-P ; DIETRICH, D ; GILLESSEN, S ; BONOMO, M ; BORNER, M ; BAUER, J ; CERNY, T ; ROCHLITZ, C ; WERNLI, M

British journal of cancer, 2004-04, Vol.90 (7), p.1312-1317 [Periódico revisado por pares]

Basingstoke: Nature Publishing Group

Texto completo disponível

Citações Citado por
8
Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: Phase II randomized study comparing two dose levels
Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: Phase II randomized study comparing two dose levels
Material Type:
Artigo 		Adicionar ao Meu Espaço

Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: Phase II randomized study comparing two dose levels

Rochlitz, Christoph ; Dreno, Brigitte ; Jantscheff, Peter ; Cavalli, Franco ; Squiban, Patrick ; Acres, Bruce ; Baudin, Martine ; Escudier, Bernard ; Heinzerling, Lucie ; Morant, Rudolf ; Herrmann, Richard ; Dietrich, Pierre-Yves ; Dummer, Reinhard

Cancer gene therapy, 2002-03, Vol.9 (3), p.289-295 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por
9
Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma?
Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma?
Material Type:
Artigo 		Adicionar ao Meu Espaço

Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma?

Wenger, C ; Stern, M ; Herrmann, R ; Rochlitz, CH ; Pless, M

Leukemia & lymphoma, 2005, Vol.46 (1), p.71-75 [Periódico revisado por pares]

United States: Informa UK Ltd

Texto completo disponível

Citações Citado por
10
Infrequent mutation of the tumour-suppressor gene Smad4 in early-stage colorectal cancer
Infrequent mutation of the tumour-suppressor gene Smad4 in early-stage colorectal cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Infrequent mutation of the tumour-suppressor gene Smad4 in early-stage colorectal cancer

MAMOT, C ; MILD, G ; REUTER, J ; LAFFER, U ; METZGER, U ; TERRACCIANO, L ; BOULAY, J-L ; HERRMANN, R ; ROCHLITZ, C

British journal of cancer, 2003-02, Vol.88 (3), p.420-423 [Periódico revisado por pares]

Basingstoke: Nature Publishing Group

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (19)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (19)
  2. Reports  (1)
  3. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de1999  (2)
  2. 1999Até2001  (4)
  3. 2002Até2003  (6)
  4. 2004Até2006  (7)
  5. Após 2006  (2)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.